Activation of coagulation in cancer patients may lead to disseminated intravascular coagulation (DIC)

DIC in cancer is driven by induction of cytokine and expression of procoagulant factors on cancer cells, such as tissue factor or factor X-activating cancer procoagulant

Derangement of vascular endothelium plays a major role in the pathogenesis of cancer-induced DIC

In the management of cancer-associated DIC anticoagulants are crucial, whereas antifibrinolytic agents may be helpful to manage excessive hyperfibrinolysis and bleeding